Repligen Corporation Company Profile (NASDAQ:RGEN)

About Repligen Corporation (NASDAQ:RGEN)

Repligen Corporation logoRepligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company's portfolio includes protein products, chromatography products, and filtration products. It provides Protein A ligands, a component of Protein A chromatography resins (media) used in the purification of virtually all monoclonal antibody (mAb)-based drugs on the market or in development. Its chromatography portfolio includes various products used in the downstream purification and quality control of biological drugs. Its OPUS pre-packed chromatography columns (PPCs) are used in the purification of clinical-stage biologics. Its filtration products include XCell Alternating Tangential Flow (ATF) Systems and Sius tangential flow filtration (TFF) cassettes. Sius TFF cassettes are used to concentrate clinical and commercial-stage biologic drugs.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Specialty & Advanced Pharmaceuticals
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:RGEN
  • CUSIP: 75991610
  • Web:
  • Market Cap: $1.38777 billion
  • Outstanding Shares: 34,080,000
Average Prices:
  • 50 Day Moving Avg: $41.16
  • 200 Day Moving Avg: $35.89
  • 52 Week Range: $26.16 - $46.81
  • Trailing P/E Ratio: 106.57
  • Foreward P/E Ratio: 53.14
  • P/E Growth: 2.91
Sales & Book Value:
  • Annual Revenue: $110.04 million
  • Price / Sales: 12.51
  • Book Value: $5.19 per share
  • Price / Book: 7.78
  • EBIDTA: $27.41 million
  • Net Margins: 11.93%
  • Return on Equity: 9.57%
  • Return on Assets: 5.64%
  • Debt-to-Equity Ratio: 0.54%
  • Current Ratio: 13.51%
  • Quick Ratio: 11.77%
  • Average Volume: 340,048 shs.
  • Beta: 1.32
  • Short Ratio: 7.49
Frequently Asked Questions for Repligen Corporation (NASDAQ:RGEN)

What is Repligen Corporation's stock symbol?

Repligen Corporation trades on the NASDAQ under the ticker symbol "RGEN."

How were Repligen Corporation's earnings last quarter?

Repligen Corporation (NASDAQ:RGEN) issued its quarterly earnings results on Thursday, May, 4th. The company reported $0.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.13 by $0.02. The firm had revenue of $30.59 million for the quarter, compared to analyst estimates of $29.28 million. Repligen Corporation had a return on equity of 9.57% and a net margin of 11.93%. The company's quarterly revenue was up 21.9% compared to the same quarter last year. During the same period in the previous year, the company posted $0.12 earnings per share. View Repligen Corporation's Earnings History.

When will Repligen Corporation make its next earnings announcement?

Repligen Corporation is scheduled to release their next quarterly earnings announcement on Wednesday, August, 2nd 2017. View Earnings Estimates for Repligen Corporation.

Where is Repligen Corporation's stock going? Where will Repligen Corporation's stock price be in 2017?

4 analysts have issued 1-year target prices for Repligen Corporation's shares. Their predictions range from $37.00 to $47.00. On average, they anticipate Repligen Corporation's share price to reach $41.00 in the next twelve months. View Analyst Ratings for Repligen Corporation.

Who are some of Repligen Corporation's key competitors?

Who are Repligen Corporation's key executives?

Repligen Corporation's management team includes the folowing people:

  • Karen A. Dawes, Independent Chairperson of the Board
  • Tony John Hunt, President, Chief Executive Officer, Director
  • Jon K. Snodgres, Chief Financial Officer
  • Howard Benjamin Ph.D., Vice President - Business Development
  • Nicolas M. Barthelemy, Independent Director
  • Glenn L. Cooper M.D., Independent Director
  • John G. Cox, Independent Director
  • Glenn P. Muir, Independent Director
  • Thomas F. Ryan Jr., Independent Director

Who owns Repligen Corporation stock?

Repligen Corporation's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Conestoga Capital Advisors LLC (3.79%), Russell Investments Group Ltd. (0.44%), Boston Advisors LLC (0.35%), Kornitzer Capital Management Inc. KS (0.29%), Summit Creek Advisors LLC (0.23%) and Great West Life Assurance Co. Can (0.16%). Company insiders that own Repligen Corporation stock include Anthony Hunt, Howard Benjamin, Jon Snodgres, Karen A Dawes and Thomas F Ryan Jr. View Institutional Ownership Trends for Repligen Corporation.

Who sold Repligen Corporation stock? Who is selling Repligen Corporation stock?

Repligen Corporation's stock was sold by a variety of institutional investors in the last quarter, including Bank of Montreal Can, Summit Creek Advisors LLC, Adams Diversified Equity Fund Inc., Eqis Capital Management Inc., Capstone Asset Management Co. and BB&T Corp. Company insiders that have sold Repligen Corporation stock in the last year include Anthony Hunt, Howard Benjamin, Jon Snodgres, Karen A Dawes and Thomas F Ryan Jr. View Insider Buying and Selling for Repligen Corporation.

Who bought Repligen Corporation stock? Who is buying Repligen Corporation stock?

Repligen Corporation's stock was acquired by a variety of institutional investors in the last quarter, including Boston Advisors LLC, Kornitzer Capital Management Inc. KS, Conestoga Capital Advisors LLC, Lebenthal Lisanti Capital Growth LLC, Russell Investments Group Ltd., Aperio Group LLC, Benin Management CORP and Great West Life Assurance Co. Can. View Insider Buying and Selling for Repligen Corporation.

How do I buy Repligen Corporation stock?

Shares of Repligen Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Repligen Corporation's stock price today?

One share of Repligen Corporation stock can currently be purchased for approximately $40.39.

MarketBeat Community Rating for Repligen Corporation (NASDAQ RGEN)
Community Ranking:  2.1 out of 5 ( )
Outperform Votes:  57 (Vote Outperform)
Underperform Votes:  76 (Vote Underperform)
Total Votes:  133
MarketBeat's community ratings are surveys of what our community members think about Repligen Corporation and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Repligen Corporation (NASDAQ:RGEN) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Hold Ratings, 2 Buy Ratings
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $41.00 (1.51% upside)

Analysts' Ratings History for Repligen Corporation (NASDAQ:RGEN)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/21/2017William BlairInitiated CoverageOutperform -> OutperformLowView Rating Details
6/28/2017Jefferies Group LLCReiterated RatingHold$33.00 -> $40.00HighView Rating Details
6/23/2017Janney Montgomery ScottBoost Price Target$42.00 -> $47.00HighView Rating Details
4/21/2017First AnalysisReiterated RatingEqual Weight$40.00LowView Rating Details
12/18/2016StephensSet Price TargetBuy$37.00N/AView Rating Details
2/22/2016Craig HallumInitiated CoverageBuyN/AView Rating Details
(Data available from 7/29/2015 forward)


Earnings History for Repligen Corporation (NASDAQ:RGEN)
Earnings by Quarter for Repligen Corporation (NASDAQ:RGEN)
Earnings History by Quarter for Repligen Corporation (NASDAQ RGEN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/4/20173/31/2017$0.13$0.15$29.28 million$30.59 millionViewListenView Earnings Details
2/22/2017Q416$0.07$0.08$24.05 million$25.60 millionViewListenView Earnings Details
11/3/2016Q316$0.08$0.08$24.39 million$24.70 millionViewN/AView Earnings Details
8/4/2016Q216$0.13$0.16$24.75 million$29.20 millionViewN/AView Earnings Details
5/5/2016Q116$0.10$0.12$22.54 million$25.10 millionViewN/AView Earnings Details
2/25/2016Q415$0.07$0.07$19.84 million$21.40 millionViewListenView Earnings Details
11/5/2015Q315$0.08$0.08$20.50 million$19.80 millionViewN/AView Earnings Details
8/6/2015Q215$0.08$0.11$20.05 million$21.50 millionViewN/AView Earnings Details
5/7/2015Q115$0.07$0.09$18.20 million$20.82 millionViewN/AView Earnings Details
3/13/2015Q414$0.04($0.01)$14.70 million$15.40 millionViewN/AView Earnings Details
11/6/2014Q314$0.04$0.04$15.60 million$15.30 millionViewN/AView Earnings Details
8/11/2014Q114$0.06$0.09$14.90 million$15.60 millionViewN/AView Earnings Details
5/8/2014Q1$0.07$0.13$15.14 million$16.33 millionViewListenView Earnings Details
3/6/2014Q413$0.14$0.10$15.88 million$10.40 millionViewListenView Earnings Details
11/7/2013Q313$0.13$0.18$16.27 million$18.80 millionViewListenView Earnings Details
8/1/2013Q2 2013$0.10$0.14$15.97 million$17.50 millionViewListenView Earnings Details
5/2/2013Q1 2013$0.07$12.82 million$16.46 millionViewListenView Earnings Details
11/8/2012Q312$0.06$8.63 million$15.10 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Repligen Corporation (NASDAQ:RGEN)
2017 EPS Consensus Estimate: $0.55
2018 EPS Consensus Estimate: $0.66
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172$0.13$0.13$0.13
Q2 20173$0.15$0.17$0.16
Q3 20173$0.13$0.14$0.13
Q4 20173$0.12$0.13$0.13
Q1 20182$0.15$0.17$0.16
Q2 20181$0.17$0.17$0.17
Q3 20181$0.16$0.16$0.16
Q4 20181$0.17$0.17$0.17
(Data provided by Zacks Investment Research)


Dividend History for Repligen Corporation (NASDAQ:RGEN)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Repligen Corporation (NASDAQ:RGEN)
Insider Ownership Percentage: 1.50%
Institutional Ownership Percentage: 97.86%
Insider Trades by Quarter for Repligen Corporation (NASDAQ:RGEN)
Institutional Ownership by Quarter for Repligen Corporation (NASDAQ:RGEN)
Insider Trades by Quarter for Repligen Corporation (NASDAQ:RGEN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/21/2017Karen A DawesDirectorSell2,521$34.12$86,016.52View SEC Filing  
3/20/2017Howard BenjaminVPSell12,216$34.62$422,917.92View SEC Filing  
3/20/2017Thomas F Ryan JrDirectorSell4,000$34.83$139,320.00View SEC Filing  
3/17/2017Jon SnodgresCFOSell1,909$34.91$66,643.19View SEC Filing  
11/28/2016Anthony HuntCEOSell5,000$33.12$165,600.00View SEC Filing  
9/14/2016Thomas F Ryan JrDirectorSell2,700$32.58$87,966.00View SEC Filing  
6/30/2016Thomas F Ryan JrDirectorSell5,000$26.60$133,000.00View SEC Filing  
6/28/2016Thomas F Ryan JrDirectorSell10,000$24.59$245,900.00View SEC Filing  
5/11/2016Howard BenjaminVPSell2,889$26.72$77,194.08View SEC Filing  
6/9/2015Howard BenjaminVPSell35,000$38.14$1,334,900.00View SEC Filing  
5/11/2015Walter C HerlihyCEOSell104,569$37.94$3,967,347.86View SEC Filing  
5/8/2015Thomas F Ryan JrDirectorSell20,000$37.19$743,800.00View SEC Filing  
3/23/2015Walter C HerlihyCEOSell24,536$31.78$779,754.08View SEC Filing  
3/19/2015James R RuscheSVPSell14,650$33.30$487,845.00View SEC Filing  
3/19/2015Thomas F Ryan JrDirectorSell10,000$32.62$326,200.00View SEC Filing  
3/19/2015Walter C HerlihyCEOSell49,695$33.08$1,643,910.60View SEC Filing  
3/18/2015Howard BenjaminVPSell15,795$32.63$515,390.85View SEC Filing  
11/19/2014Walter C HerlihyCEOSell51,386$23.43$1,203,973.98View SEC Filing  
11/13/2014Thomas F Ryan JrDirectorSell10,000$23.81$238,100.00View SEC Filing  
11/11/2014Howard BenjaminVPSell30,000$23.56$706,800.00View SEC Filing  
11/10/2014Michael A GriffithDirectorSell23,342$22.90$534,531.80View SEC Filing  
8/13/2014Howard BenjaminVPSell40,000$20.34$813,600.00View SEC Filing  
6/27/2014Thomas F Ryan JrDirectorSell10,000$22.41$224,100.00View SEC Filing  
6/24/2014Thomas F Ryan JrDirectorSell10,000$21.78$217,800.00View SEC Filing  
6/11/2014Walter C HerlihyCEOSell60,335$20.11$1,213,336.85View SEC Filing  
6/9/2014James R RuscheSVPSell30,000$20.19$605,700.00View SEC Filing  
6/6/2014Daniel P WittSVPSell47,709$20.56$980,897.04View SEC Filing  
4/15/2014Daniel P WittSVPBuy10,000$3.05$30,500.00View SEC Filing  
8/8/2013James R RuscheSVPSell30,000$10.01$300,300.00View SEC Filing  
6/21/2013Karen A DawesDirectorBuy1,000$7.70$7,700.00View SEC Filing  
5/17/2013Thomas F Ryan JrDirectorSell21,000$8.97$188,370.00View SEC Filing  
5/15/2013Thomas F Ryan JrDirectorSell86,039$9.01$775,211.39View SEC Filing  
5/15/2013Walter C HerlihyCEOSell40,000$8.97$358,800.00View SEC Filing  
9/21/2012Glenn L Md CooperDirectorBuy10,000$6.09$60,900.00View SEC Filing  
8/16/2012Michael A GriffithDirectorBuy2,000$4.88$9,760.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Repligen Corporation (NASDAQ:RGEN)
Latest Headlines for Repligen Corporation (NASDAQ:RGEN)
DateHeadline logo Analysts Expect Repligen Corporation (RGEN) Will Announce Quarterly Sales of $31.42 Million - July 28 at 7:55 PM logoRepligen to Report Second Quarter 2017 Financial Results - July 28 at 7:16 AM logoZacks: Analysts Expect Repligen Corporation (NASDAQ:RGEN) to Announce $0.15 Earnings Per Share - July 26 at 8:55 AM logoWilliam Blair Initiates Coverage on Repligen Corporation (NASDAQ:RGEN) - July 22 at 2:52 PM logoCritical Review: Repligen Corporation (RGEN) versus Salix Pharmaceuticals (SLXP) - July 13 at 8:10 AM logoRepligen Corporation (RGEN) Receives Average Rating of "Buy" from Analysts - July 11 at 10:06 AM logoRepligen Corporation (RGEN) Stock Rating Lowered by Zacks Investment Research - July 5 at 10:35 AM logoQ3 2017 EPS Estimates for Repligen Corporation (NASDAQ:RGEN) Decreased by First Analysis - July 3 at 7:58 AM logo Analysts Expect Repligen Corporation (RGEN) Will Post Quarterly Sales of $31.47 Million - July 1 at 7:38 AM logoZacks: Analysts Expect Repligen Corporation (RGEN) to Post $0.15 EPS - June 30 at 12:20 AM logoRepligen Corporation (RGEN) Given Hold Rating at Jefferies Group LLC - June 28 at 11:28 AM logoResearch Analysts Issue Forecasts for Repligen Corporation's Q4 2017 Earnings (RGEN) - June 28 at 8:28 AM logoRepligen (RGEN) Commences $100M Common Stock Offering - June 27 at 7:36 PM logoRepligen Corporation (RGEN) Updates On Merger Agreement with Spectrum - M&A Slideshow - June 27 at 7:36 PM logoRepligen Corporation Prices Public Offering of Shares of Common Stock - June 27 at 7:36 PM logoRepligen Corporation to Post Q3 2017 Earnings of $0.14 Per Share, Craig Hallum Forecasts (RGEN) - June 27 at 8:22 AM logoRepligen Corporation Announces Proposed Public Offering of Shares of Common Stock - June 27 at 7:49 AM logoRepligen Corporation (RGEN) Upgraded at BidaskClub - June 24 at 4:26 PM logoRepligen Corporation (RGEN) PT Raised to $47.00 at Janney Montgomery Scott - June 24 at 10:40 AM logoRepligen to buy filtration company Spectrum for $359 million in cash and stock - June 23 at 9:35 AM logoRepligen Corporation and Spectrum, Inc. to Join Forces - June 23 at 7:34 AM logoETFs with exposure to Repligen Corp. : June 19, 2017 - June 20 at 2:24 AM logoAnalyzing Repligen Corporation (RGEN) and Check-Cap (CHEK) - June 17 at 8:32 PM logoRepligen Corp. :RGEN-US: Earnings Analysis: Q1, 2017 By the Numbers : June 16, 2017 - June 16 at 3:31 PM logoRepligen Corporation (RGEN) Given Consensus Recommendation of "Buy" by Brokerages - June 14 at 4:54 PM logoRepligen Corporation (RGEN) Downgraded by BidaskClub - June 14 at 4:40 PM logoContrasting Repligen Corporation (RGEN) and DARA Biosciences (DARA) - June 14 at 12:45 PM logoRepligen Corporation (RGEN) Rating Increased to Buy at Zacks Investment Research - June 14 at 7:42 AM logoRepligen Co. (RGEN) Expected to Post Quarterly Sales of $31.47 Million - June 7 at 8:50 AM logoRepligen Co. (RGEN) Upgraded by Zacks Investment Research to "Buy" - June 7 at 7:36 AM logoRepligen Co. (RGEN) Downgraded by Zacks Investment Research to "Hold" - June 6 at 7:58 AM logo$0.15 Earnings Per Share Expected for Repligen Co. (RGEN) This Quarter - June 5 at 10:12 PM logoRepligen to Present at Jefferies’ 2017 Global Annual Healthcare Conference - May 31 at 12:50 PM logoRepligen to Participate in 14th Annual Craig-Hallum Institutional Investor Conference - May 24 at 9:46 AM logoFirst Analysis Analysts Cut Earnings Estimates for Repligen Co. (RGEN) - May 24 at 7:30 AM logoZacks: Repligen Co. (RGEN) Given $38.00 Consensus Price Target by Analysts - May 16 at 6:42 PM logo$31.47 Million in Sales Expected for Repligen Co. (RGEN) This Quarter - May 12 at 3:44 PM logoRepligen Co. (RGEN) Lifted to "Buy" at Zacks Investment Research - May 11 at 9:44 AM logoRepligen Co. (RGEN) Expected to Post Earnings of $0.16 Per Share - May 10 at 7:42 AM logoRepligen to Present at Bank of America Merrill Lynch 2017 Healthcare Conference - May 9 at 2:48 PM logoEquities Analysts Issue Forecasts for Repligen Co.'s Q2 2017 Earnings (RGEN) - May 8 at 8:21 AM logoQ3 2017 EPS Estimates for Repligen Co. (RGEN) Boosted by Jefferies Group - May 5 at 10:56 AM logoTrade of the Day: Repligen (NASDAQ:RGEN) - May 5 at 8:26 AM logoEdited Transcript of RGEN earnings conference call or presentation 4-May-17 12:30pm GMT - May 5 at 12:45 AM logoRepligen Co. (RGEN) Releases Quarterly Earnings Results, Beats Estimates By $0.02 EPS - May 4 at 10:26 PM logoInvestor Network: Repligen Corporation to Host Earnings Call - May 4 at 7:45 PM logoRepligen Reports First Quarter 2017 Financial Results - May 4 at 7:45 PM logoRepligen tops Street 1Q forecasts - May 4 at 7:54 AM logoRepligen (RGEN) Receiving Somewhat Favorable Press Coverage, AlphaOne Reports - May 3 at 1:03 AM logoETFs with exposure to Repligen Corp. : May 1, 2017 - May 1 at 6:48 PM



Repligen Corporation (RGEN) Chart for Saturday, July, 29, 2017

This page was last updated on 7/29/2017 by Staff